1-9 of 9
Janet M. Leeds, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 466.
https://doi.org/10.1182/blood-2019-123986
Published: 2019
Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3981.
https://doi.org/10.1182/blood-2019-124231
Published: 2019
Journal Articles

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S Khodadoust, MDPhD, Youn H. Kim, MD, Javier Munoz, MD, Manish R Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Andrew Steele, Anjali Pandey, PhD, Matt R Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn Michelson, MD, Gregory P. Coffey, PhD, John T Curnutte, MD PhD, Paul A. Hamlin, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1001.
https://doi.org/10.1182/blood-2018-99-119944
Published: 2018
Journal Articles

Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics

Janet M. Leeds, PhD, Alice Ke, Karen Rowland Yeo, John T Curnutte, MD PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3663.
https://doi.org/10.1182/blood.V130.Suppl_1.3663.3663
Published: 2017
Journal Articles

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Gregory P. Coffey, PhD, Jiajia Feng, MD, Andreas Betz, PhD, Anjali Pandey, PhD, Matt Birrell, B.S., Janet M. Leeds, PhD, Kenneth Der, PhD, Sabah Kadri, PhD, Pin Lu, PhD, Jeremy Segal, PhD, Lynn Wang, MD PhD, Glenn Michelson, MD, John T Curnutte, MD PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2782.
https://doi.org/10.1182/blood.V130.Suppl_1.2782.2782
Published: 2017
Journal Articles

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Mark Crowther, MD, Genmin Lu, PhD, Janet M. Leeds, PhD, Joyce Lin, BS, Pamela B. Conley, PhD, Alexander Gold, MD, Stuart J. Connolly, MD, John T. Curnutte, MD PhD
Journal: Blood
Blood (2016) 128 (22): 143.
https://doi.org/10.1182/blood.V128.22.143.143
Published: 2016
Journal Articles

Andexanet Alfa Reverses Anticoagulation Effects of Enoxaparin and Associated Bleeding in a Rabbit Acute Hemorrhage Model

Polly Pine, PhD, Genmin Lu, PhD, Deogracias Canivel, Pratikhya Pratikhya, BS, MSc, Francis DeGuzman, PhD, Mark Karbarz, PhD, Kentaro Takeda, BS, John Malinowski, PhD, Janet M. Leeds, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD
Journal: Blood
Blood (2016) 128 (22): 1445.
https://doi.org/10.1182/blood.V128.22.1445.1445
Published: 2016
Journal Articles

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

Paul A Hamlin, Jr., MD, Ian Flinn, MD, Nina wagner-Johnston, MD, Jan A Burger, MD PhD, Glenn Michelson, MD, Anjali Pandey, PhD, Matt Birrell, Greg P. Coffey, PhD, Janet M Leeds, PhD, John T. Curnutte, MDPhD, Manish R. Patel, MD
Journal: Blood
Blood (2015) 126 (23): 3929.
https://doi.org/10.1182/blood.V126.23.3929.3929
Published: 2015
Journal Articles

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Manish Patel, Paul Hamlin, MD, Donald K Strickland, MD, Anjali Pandey, PhD, Greg Coffey, PhD, Janet M Leeds, PhD, Gallia G. Levy, MD PhD, John T. Curnutte, MDPhD, Nina Wagner-Johnston, Ian W. Flinn, MD
Journal: Blood
Blood (2014) 124 (21): 3103.
https://doi.org/10.1182/blood.V124.21.3103.3103
Published: 2014